La vendita allo scoperto per Prelude Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Prelude Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Prelude Therapeutics (NASDAQ:PRLD) Azioni, Report sulle vendite allo scoperto

Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics Inc

Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) affirms FY2024 sales outlook from $81.00 million-83.00 million to $81.00 million-83.00 million.

News

Guidance

SGHT

Sight Sciences Affirms FY2024 Sales Guidance from $81.00M-83.00M to $81.00M-83.00M

ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $9.58 million in sales this quarter. This is a 17.62 percent increase over sales of $8.15 million the same period last year.

Earnings

AACG

ATA Creativity Glb Q3 Adj ADS $(0.06) Down From $(0.02) YoY, Sales $9.58M Up From $8.15M YoY

Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares are surging in Thursday&#8217;s after-hours session after the company reported better-than-expected financial results<a href="https://www.benzinga.com/pressreleases/24/11/b41823433/doximity-announces-fiscal-2025-second-quarter-financial-results"> for the second quarter</a>.
<ul>
<li>Q2 Revenue: $136.83 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $127.15 million</li>
</ul>
<ul>
<li>Q2 Adjusted EPS: 30 cents, versus estimates of 25 cents</li>
</ul>
Revenue was up 20% year-over-year. The company generated $68.3 million in operating cash flow and $66.8 million in free cash flow during the quarter. Free cash flow was up 475% year-over-year. 
&#8220;Our clinical workflow tools saw record use in the second quarter with over 600,000 unique active prescribers. We&#8217;re proud to help physicians save time, so they can provide better care for their patients,&#8221; said Jeff Tangney, co-founder and CEO of Doximity.
Guidance: Doximity expects third-quarter revenue to be in the range of $152 million to $153 million. The company anticipates third-quarter Adjusted EBITDA of $83 million to $84 million.
Doximity sees full-year revenue between $535 million and $540 million. The company expects full-year Adjusted EBITDA to be in the range of $274 million to $279 million.
DOCS Price Action: <a href="https://www.benzinga.com/quote/DOCS" target="_blank" rel="noreferrer noopener">Doximity shares</a> were up 37.91% after hours at $59.88 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41828399/fortinet-q3-earnings-revenue-beat-eps-beat-billings-up-6-shares-slide">Fortinet Q3 Earnings: Revenue Beat, EPS Beat, Billings Up 6%, Shares Slide</a></li>
</ul>
Photo: Courtesy of Doximity.

Health Care

After-Hours Center

Movers

DOCS

Doximity Reports Strong Q2 Earnings Results, Shares Soar

AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.57 by 7.02 percent. The company reported quarterly sales of $687.509 million which beat the analyst consensus estimate of $671.445 million by 2.39 percent. This is a 19.44 percent decrease over sales of $853.463 million the same period last year.

Earnings Beats

AMN Healthcare Services Q3 2024 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $687.509M Beat $671.445M Estimate

WIIM

Trade Desk shares are trading lower despite the company reporting better-than-expected Q3 financial results.

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) reported quarterly sales of $72.307 million which beat the analyst consensus estimate of $60.337 million by 19.84 percent. This is a 25.35 percent increase over sales of $57.683 million the same period last year.

GSAT

Globalstar Q3 Sales $72.307M Beat $60.337M Estimate

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.34 by 88.24 percent. This is a 77.78 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $621.40 million which missed the analyst consensus estimate of $627.15 million by 0.92 percent. This is a 21.60 percent increase over sales of $511.01 million the same period last year.

Earnings Misses

CORRECTION: Evolent Health Q3 Adj $0.04 Misses $0.34 Estimate, Sales $621.40M Miss $627.15M Estimate

Stantec Expects FY24 Net Revenue Growth Outlook From 12% - 15% To 14.5% - 15.0%, Adjusted EPS Growth Forecast From 12% - 16% To 16% -18%

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 18.18 percent. The company reported quarterly sales of $24.124 million which beat the analyst consensus estimate of $18.281 million by 31.96 percent. This is a 0.08 percent decrease over sales of $24.144 million the same period last year.

NKTR

Nektar Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate, Sales $24.124M Beat $18.281M Estimate

Red Rock Resorts Q3 2024 Adj EPS $0.48 Misses $0.52 Estimate, Sales $468.00 Beats  $461.67M Estimate

VCTR

Victory Capital Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its quarterly dividend.

Volato Group, Inc. ("Volato," or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) is excited to announce that Vaunt has reached an important milestone, with the first flyExclusive flights now available on the platform. This is the start of a larger effort to expand the flight options available to Vaunt members, with more additions and features planned in the coming months.
flyExclusive brings a range of light, midsize, and super-midsize jets to Vaunt, significantly expanding the choices available to users. This first step lays the groundwork for future growth, as Volato works to steadily increase flight availability and deliver a more robust platform for private travelers.

SOAR

Volato Group Announces Vaunt Reaches First Milestone With flyExclusive Flights Now Available On The Platform

Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 75 percent. The company reported quarterly sales of $23.476 million which missed the analyst consensus estimate of $29.379 million by 20.09 percent. This is a 9.73 percent decrease over sales of $26.006 million the same period last year.

LPRO

Open Lending Q3 2024 GAAP EPS $0.01 Misses $0.04 Estimate, Sales $23.476M Miss $29.379M Estimate

Despite claiming over 100,000 lives annually, the U.S. overdose crisis received minimal attention during the recent presidential campaign, which concluded with Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/11/41776510/cannabis-industry-leaders-react-to-trump-victory-expect-changes">victory</a>. This oversight comes as overdose deaths continue to rise among Black and Indigenous Americans, revealing a growing racial disparity in the epidemic.
<h3 class="wp-block-heading">Rising Racial Disparities In Overdose Deaths</h3>
According to a Stateline analysis of federal data <a href="https://kentuckylantern.com/2024/11/04/overdose-deaths-are-rising-among-black-and-indigenous-americans/">covered</a> by Tim Henderson, overdose deaths among white Americans have declined, but deaths among people of color have increased. In 2023, Black and Native Americans experienced overdose death rates of 49.5 and 39.8 per 100,000 people, respectively, surpassing white rates. Health experts attribute this to a lack of targeted resources and funding in nonwhite communities.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;It is our contention that Black harm reduction isn't about drug use, it's about the harms of not being a white person in this country,&#8221; said Tracie Gardner, co-director of the National Black Harm Reduction Network. Communities of color often struggle to access harm reduction services, which are predominantly designed and led by white institutions.
<h3 class="wp-block-heading">Minimal Campaign Attention</h3>
Throughout the campaign, Trump and his opponent, Vice President Kamala Harris, <a href="https://www.benzinga.com/markets/cannabis/24/10/41299527/kamala-harris-defends-immigration-policy-at-latino-town-hall-criticizes-trumps-border-stance">focused largely on border security and drug enforcement</a> rather than harm reduction strategies.&nbsp;
As a recent Fitler Mag <a href="https://filtermag.org/overdose-presidential-election/">article</a> notes, Trump&#8217;s official platform emphasized escalating the drug war, proposing measures like deploying the U.S. Navy to impose a &#8220;full Fentanyl Blockade&#8221; and cracking down on cartels. Harris, while mentioning a commitment to ending the opioid epidemic, highlighted her background in prosecutions and supported increased border security measures.
Public health experts criticize this approach for failing to address the root causes of the crisis. Kassandra Frederique, executive director of the Drug Policy Alliance, noted that efforts have &#8220;ultimately fallen short of the scale and magnitude this crisis demands.&#8221;
<h3 class="wp-block-heading">Rising Demand For Narcan</h3>
Amid this policy void, demand for naloxone—commonly known by the brand name Narcan—is increasing sharply. Over 250 companies, universities and organizations have pledged to provide free doses of the overdose-reversing medication, <a href="https://www.npr.org/sections/shots-health-news/2024/10/08/nx-s1-5145832/250-companies-schools-and-organizations-pledge-to-provide-overdose-antidote-naloxone">according</a> to NPR. Major corporations like Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and the National Hockey League are participating in this national effort to curb fatalities.
White House officials noted that the wider availability of naloxone has contributed to a recent 10% decline in overall overdose deaths. &#8220;From airlines to classrooms, from offices to sports arenas, we are grateful to have hundreds of voluntary commitments from organizations and businesses across the country,&#8221; stated Dr. Rahul Gupta, the Biden administration&#8217;s drug czar, prior to the election.
However, experts caution that fatalities remain high, especially among marginalized communities.
<h3 class="wp-block-heading">Emergent BioSolutions Sees Stock Surge</h3>
Meanwhile, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), the manufacturer of Narcan, has seen its stock perform strongly in 2024. With a diverse portfolio addressing public health threats, the company&#8217;s financial recovery and strategic government contracts position it favorably in the market, <a href="https://www.insidermonkey.com/blog/emergent-biosolutions-inc-ebs-a-standout-among-best-performing-cheap-stocks-in-2024-1371074/">noted</a> Insider Monkey. EBS reported significant revenue growth and reduced debt, contributing to a year-to-date share price gain of over 280%.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31549189/fda-approves-over-the-counter-sale-of-opioid-reversal-drug-narcan">FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan</a>
Analysts attribute part of Emergent&#8217;s success to the increasing recognition of naloxone&#8217;s importance in combating the overdose crisis. As more organizations stock Narcan, the company&#8217;s role becomes ever more critical.
<h3 class="wp-block-heading">Barriers To Harm Reduction Access Persist</h3>
As the new administration takes office, the neglect of the overdose crisis in election debates raises questions about the future of <a href="http://benzinga.com/topic/harm-reduction">harm reduction</a> policies under the new administration. Advocates urge the government to prioritize effective strategies over punitive measures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41780260/canopy-growth-and-other-top-cannabis-companies-to-report-earnings-will-results-get-pot-stocks-on">Canopy Growth And Other Top Cannabis Companies To Report Earnings: Will Results Get Pot Stocks On Track Following Post-Election Dip?</a></li>
</ul>

Cannabis

Government

Politics

AMZN

Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise

ADMA

ADMA Biologics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and FY25 revenue guidance.

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) lowers FY2024 sales outlook from $45.00 million-50.00 million to $43.00 million-45.00 million.

TACT

Transact Technologies Lowers FY2024 Sales Guidance from $45.00M-50.00M to $43.00M-$45.00M  VS Est. $47.16M

Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.04 by 250 percent. This is a 366.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $292.765 million which beat the analyst consensus estimate of $289.601 million by 1.09 percent. This is a 6.45 percent decrease over sales of $312.944 million the same period last year.

FNKO

Funko Q3 2024 Adj. EPS $0.14 Beats $0.04 Estimate, Sales $292.765M Beat $289.601M Estimate

System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. The company reported quarterly sales of $88.832 million which beat the analyst consensus estimate of $86.629 million by 2.54 percent. This is a 1.15 percent increase over sales of $87.818 million the same period last year.

System1 Q3 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $88.832M Beat $86.629M Estimate

Mexco Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) reported quarterly earnings of $0.15 per share. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported $1.75 million in sales this quarter. This is a 24.32 percent increase over sales of $1.41 million the same period last year.

Mexco Energy Q2 EPS $0.15 Up From $0.12 YoY, Sales $1.75M Up From $1.41M YoY

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

Prelude Therapeutics (PRLD) announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a ...

Prelude Therapeutics presents new data from Phase 1 trial of PRT3789

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position

Jeffrey Hung, an analyst from Morgan Stanley, maintained the Sell rating on Prelude Therapeutics (PRLD – Research Report). The associated price tar...

Cautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market Skepticism

Analyst Peter Lawson of Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), reducing the price target to $1.00. Pet...

Prelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial Challenges

Barclays analyst Peter Lawson lowered the firm's price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the s...

Prelude Therapeutics price target lowered to $1 from $3 at Barclays

Prelude Therapeutics (PRLD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns fr...

Optimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial Results

"Our third quarter was marked by dedicated execution and the achievement of essential milestones for our lead clinical programs targeting SMARCA2,"...

Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price target at ...

Prelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy Rating

Prelude Therapeutics GAAP EPS of -$0.43, revenue of $3M

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

PRLD

Press Releases

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Comments

Prelude Therapeutics

Vendite allo scoperto

Prelude Therapeutics (NASDAQ:PRLD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO